Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hoth Therapeutics ( (HOTH) ) has issued an announcement.
On April 1, 2026, Hoth Therapeutics entered a securities purchase agreement with institutional investors to sell 2,857,144 shares of common stock at $0.70 per share in a registered direct offering, with closing completed on April 2, 2026. For each share, investors received an unregistered warrant exercisable after six months at $0.85 for five years, together generating approximately $2 million in gross proceeds to support working capital and general corporate purposes.
The company also granted H.C. Wainwright & Co. placement agent fees, expense reimbursements and warrants equal to 5% of the shares sold, while structuring investor warrants with ownership caps and customary anti-dilution adjustments. Concurrently, Hoth suspended use of its existing at-the-market prospectus, signaling a near-term shift toward this structured financing while preserving its broader ATM facility for potential future use.
More about Hoth Therapeutics
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs. The company operates as an early-stage R&D catalyst, advancing drug candidates from the bench into pre-clinical and clinical testing through collaborations with scientists, clinicians and key opinion leaders.
Average Trading Volume: 585,028
Technical Sentiment Signal: Sell
Current Market Cap: $8.9M
See more data about HOTH stock on TipRanks’ Stock Analysis page.